like pls_老虎社区_美港股上老虎

Dttk
2021-12-20

like pls

Coherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar

Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food a

Coherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":693608147,"tweetId":"693608147","gmtCreate":1640010056700,"gmtModify":1640010056973,"author":{"id":3572939968720880,"idStr":"3572939968720880","authorId":3572939968720880,"authorIdStr":"3572939968720880","name":"Dttk","avatar":"https://static.tigerbbs.com/82269b01d70f98d5770f4418d3911ef9","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>like pls</p></body></html>","htmlText":"<html><head></head><body><p>like pls</p></body></html>","text":"like pls","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693608147","repostId":1189443139,"repostType":4,"repost":{"id":"1189443139","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640008567,"share":"https://www.laohu8.com/m/news/1189443139?lang=&edition=full","pubTime":"2021-12-20 21:56","market":"us","language":"en","title":"Coherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=1189443139","media":"Dow Jones","summary":"Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food a","content":"<p>Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food and Drug Administration approved Yusimry, a Humira biosimilar product.</p>\n<p>Yusimry is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.</p>\n<p>Approval was based on a data package that demonstrated the biosimilarity of Yusimry to the reference product, Humira.</p>\n<p>Coherus said it plans to launch Yusimry in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie Inc.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 21:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food and Drug Administration approved Yusimry, a Humira biosimilar product.</p>\n<p>Yusimry is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.</p>\n<p>Approval was based on a data package that demonstrated the biosimilarity of Yusimry to the reference product, Humira.</p>\n<p>Coherus said it plans to launch Yusimry in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie Inc.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CHRS":"Coherus Biosciences"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189443139","content_text":"Coherus BioSciences Inc. shares rose 7.2%, to $17.66, premarket Monday after it said the U.S. Food and Drug Administration approved Yusimry, a Humira biosimilar product.\nYusimry is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.\nApproval was based on a data package that demonstrated the biosimilarity of Yusimry to the reference product, Humira.\nCoherus said it plans to launch Yusimry in the U.S. on or after July 1, 2023, per the terms of an agreement with Humira manufacturer AbbVie Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1050,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Coherus Shares Up 7.2% After FDA Approves Yusimry, Humira Biosimilar

评论（1）

热议股票